Amended Statement of Beneficial Ownership (sc 13d/a)
March 18 2021 - 2:06PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
DC 20549
SCHEDULE
13D/A
UNDER
THE SECURITIES EXCHANGE ACT OF 1934
(Amendment
No. 1)*
GENE
BIOTHERAPEUTICS, INC.
(Name
of Issuer)
Common
Stock
(Title
of Class of Securities)
86767104
1
(CUSIP
Number)
Christopher
J. Jemapete
6888
S. Irvington Court
Aurora,
CO 80016
(303)
877-3033
(Name,
Address and Telephone Number of Person
Authorized
to Receive Notices and Communications)
March
16, 2021
(Date
of Event which Requires Filing of This Statement)
If
the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule
13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box [_].
Note:
Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule
13d-7 for other parties to whom copies are to be sent.
*
The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to
the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided
in a prior cover page.
The
information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section
18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the Notes).
CUSIP
No. 86767104 1
|
Schedule
13D/A
|
Page
2 of 4 Pages
|
1
|
NAMES
OF REPORTING PERSONS
|
|
Christopher
J. Jemapete
|
|
|
2
|
CHECK
THE APPROPRIATE BOX IF A MEMBER OF A GROUP
|
|
(a)
[ ]
|
|
(b)
[ ]
|
|
|
3
|
SEC
USE ONLY
|
|
|
|
|
4
|
SOURCE
OF FUNDS
|
|
PF
|
|
|
5
|
CHECK
BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED
|
|
PURSUANT
TO ITEMS 2(d) OR 2(e) [_]
|
|
|
6
|
CITIZENSHIP
OR PLACE OF ORGANIZATION
|
|
United
States
|
NUMBER
OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
|
|
7
|
SOLE
VOTING POWER
|
|
4,000,000
|
|
|
8
|
SHARED
VOTING POWER
0
|
|
|
9
|
SOLE
DISPOSITIVE POWER
|
|
4,000,000
|
|
|
10
|
SHARED
DISPOSITIVE POWER
0
|
11
|
AGGREGATE
AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
|
|
4,000,000
|
|
|
12
|
CHECK
IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES [ ]
|
|
|
13
|
PERCENT
OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
|
|
27.6%
(1)
|
|
|
14
|
TYPE
OF REPORTING PERSON*
|
|
IN
|
(1)
|
Based
on 14,489,399 shares of the issuer’s common stock issued and outstanding as of
May 22, 2020, as reported on the issuer’s Current Report on Form 8-K filed with
the Securities and Exchange Commission on May 28, 2020.
|
CUSIP
No. 86767104 1
|
Schedule
13D/A
|
Page
3 of 4 Pages
|
Item
1. Security and Issuer.
This
Amendment No. 1 to Schedule 13D relates to the common stock of Gene Biotherapeutics, Inc., a Delaware corporation (the “Company”
or the “Issuer”). The address of the Issuer’s principal executive office is 11230 Sorrento Valley Road, Suite
220, San Diego, California 92122.
Item
2. Identity and Background.
(a)
|
|
Christopher
J. Jemapete
|
|
|
|
(b)
|
|
6888
S. Irvington Court, Aurora, CO 80016
|
|
|
|
(c)
|
|
Retired
|
|
|
|
(d)
|
|
During
the last five years, Mr. Jemapete has not been convicted in a criminal proceeding (excluding traffic violations or similar
misdemeanors).
|
|
|
|
(e)
|
|
During
the last five years, Mr. Jemapete was not a party to a civil proceeding of a judicial or administrative body of competent
jurisdiction, as a result of which proceeding was or is subject to a judgment, decree or final order enjoining future violations
of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect
to such laws.
|
|
|
|
(f)
|
|
United
States
|
Item
3. Source and Amount of Funds or Other Consideration.
Mr.
Jemapete purchased an aggregate of 500,000 shares of the issuer’s common stock in a series of transactions effected between
March 16, 2021 and March 17, 2021. Mr. Jemapete used his personal funds for these purchases.
Item
4. Purpose of Transaction.
Mr.
Jemapete purchased an aggregate of 500,000 of the issuer’s common stock in a series of transactions effected between March
16, 2021 and March 17, 2021 via open market purchases. These securities were not acquired and are not held for the purpose of
or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held
in connection with or as a participant in any transaction having that purpose or effect.
Item
5. Interest in Securities of the Issuer.
(a)
4,000,000 shares, or approximately 27.6% (based on 14,489,399 shares of the issuer’s common stock issued and outstanding
as of May 22, 2020, as reported on the issuer’s Current Report on Form 8-K filed with the Securities and Exchange Commission
on May 28, 2020).
(b)
|
Sole
voting power: 4,000,000 shares
|
|
Shared
voting power: 0 shares
|
|
Sole
dispositive power: 4,000,000 shares
|
|
Shared
dispositive power: 0 shares
|
(c)
The reporting person effected open market purchases of the following shares of the issuer’s common stock during the past
60 days:
Date
|
|
Aggregate
No. of Shares Purchased
|
|
|
Average
Price Per Share
|
|
March 16, 2021
|
|
|
20,000
|
|
|
$
|
0.0378
|
|
March 16, 2021
|
|
|
280,000
|
|
|
$
|
0.0400
|
|
March 17, 2021
|
|
|
1,000
|
|
|
$
|
0.0401
|
|
March 17, 2021
|
|
|
500
|
|
|
$
|
0.0402
|
|
March 17, 2021
|
|
|
23,500
|
|
|
$
|
0.0402
|
|
March 17, 2021
|
|
|
20,000
|
|
|
$
|
0.0378
|
|
March 17, 2021
|
|
|
5,000
|
|
|
$
|
0.0404
|
|
March 17, 2021
|
|
|
20,000
|
|
|
$
|
0.0379
|
|
March 17, 2021
|
|
|
5,000
|
|
|
$
|
0.0406
|
|
March 17, 2021
|
|
|
20,000
|
|
|
$
|
0.0381
|
|
CUSIP
No. 86767104 1
|
Schedule
13D/A
|
Page
4 of 4 Pages
|
Date
|
|
Aggregate
No. of Shares Purchased
|
|
|
Average
Price Per Share
|
|
March 17, 2021
|
|
|
5,000
|
|
|
$
|
0.0408
|
|
March 17, 2021
|
|
|
20,000
|
|
|
$
|
0.0383
|
|
March 17, 2021
|
|
|
11,000
|
|
|
$
|
0.0410
|
|
March 17, 2021
|
|
|
1,000
|
|
|
$
|
0.0425
|
|
March 17, 2021
|
|
|
8,000
|
|
|
$
|
0.0425
|
|
March 17, 2021
|
|
|
3,116
|
|
|
$
|
0.0425
|
|
March 17, 2021
|
|
|
10,000
|
|
|
$
|
0.0425
|
|
March 17, 2021
|
|
|
5,000
|
|
|
$
|
0.0425
|
|
March 17, 2021
|
|
|
40,000
|
|
|
$
|
0.0425
|
|
March 17, 2021
|
|
|
1,884
|
|
|
$
|
0.0414
|
|
(d)
Not applicable.
(e)
Not applicable.
Item
6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.
Not
applicable.
Item
7. Material to be Filed as Exhibits.
None.
SIGNATURE
After
reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true,
complete and correct.
|
CHRISTOPHER
J. JEMAPETE
|
|
|
Dated:
March 18, 2021
|
/s/
Christopher J. Jemapete
|
Taxus Cardium Pharmaceut... (CE) (USOTC:CRXM)
Historical Stock Chart
From Aug 2024 to Sep 2024
Taxus Cardium Pharmaceut... (CE) (USOTC:CRXM)
Historical Stock Chart
From Sep 2023 to Sep 2024